Heigener DF - Search Results

1

Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.

Heigener DF, Reck M. Heigener DF, et al. Adv Ther. 2011 Feb;28(2):126-33. doi: 10.1007/s12325-010-0096-4. Epub 2010 Dec 16. Adv Ther. 2011. PMID: 21181318 Review.

2

[Non-small cell lung cancer - diagnostics and stage-adapted therapy].

Heigener DF, Reck M, Gatzemeier U. Heigener DF, et al. Med Klin (Munich). 2007 Dec 15;102(12):981-8; quiz 989-90. doi: 10.1007/s00063-007-1122-4. Med Klin (Munich). 2007. PMID: 18075718 Review. German.

3

[Chemotherapy of malignant pleural mesothelioma: have we made any progress?].

Reck M, Heigener DF, Gatzemeier U. Reck M, et al. Among authors: heigener df. Zentralbl Chir. 2008 Jun;133(3):238-42. doi: 10.1055/s-2008-1004809. Zentralbl Chir. 2008. PMID: 18563688 Review. German.

4

Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.

Schneider CP, Heigener D, Schott-von-Römer K, Gütz S, Laack E, Digel W, Guschall WR, Franke A, Bodenstein H, Schmidtgen C, Reck M. Schneider CP, et al. J Thorac Oncol. 2008 Dec;3(12):1446-53. doi: 10.1097/JTO.0b013e31818ddcaa. J Thorac Oncol. 2008. PMID: 19057271 Free article. Clinical Trial.

5

Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study.

Reck M, Frickhofen N, Cedres S, Gatzemeier U, Heigener D, Fuhr HG, Thall A, Lanzalone S, Stephenson P, Ruiz-Garcia A, Chao R, Felip E. Reck M, et al. Lung Cancer. 2010 Nov;70(2):180-7. doi: 10.1016/j.lungcan.2010.01.016. Epub 2010 Feb 25. Lung Cancer. 2010. PMID: 20188433 Clinical Trial.

6

Diagnostics and staging procedures in non-small cell lung cancer - is less more?

Heigener DF, Diemel KD, Reck M, Gatzemeier U. Heigener DF, et al. Clin Respir J. 2008 Apr;2(2):67-73. doi: 10.1111/j.1752-699X.2008.00049.x. Clin Respir J. 2008. PMID: 20298309 Review.

7

Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.

Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, Krzakowski M, Heigener D. Reck M, et al. J Thorac Oncol. 2010 Oct;5(10):1616-22. doi: 10.1097/JTO.0b013e3181f1c7b0. J Thorac Oncol. 2010. PMID: 20736854 Free article. Clinical Trial.

8

Reviewing the safety of erlotinib in non-small cell lung cancer.

Reck M, Mok T, Wolf J, Heigener D, Wu YL. Reck M, et al. Expert Opin Drug Saf. 2011 Jan;10(1):147-57. doi: 10.1517/14740338.2011.540799. Epub 2010 Dec 8. Expert Opin Drug Saf. 2011. PMID: 21138395 Review.

9

Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.

Heigener DF, Wu YL, van Zandwijk N, Mali P, Horwood K, Reck M. Heigener DF, et al. Lung Cancer. 2011 Nov;74(2):274-9. doi: 10.1016/j.lungcan.2011.02.017. Epub 2011 Mar 24. Lung Cancer. 2011. PMID: 21439671 Clinical Trial.

10

Non-small cell lung cancer in never-smokers: a new disease entity?

Heigener DF. Heigener DF. Onkologie. 2011;34(4):202-7. doi: 10.1159/000326839. Epub 2011 Mar 18. Onkologie. 2011. PMID: 21447981 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

68 results

Search Page

Filters